- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05793814
Assess the Effects of a Limosilactobacillus Supplement on Recurrence of UTI in Healthy Women During a 6-month Period
March 20, 2023 updated by: Church & Dwight Company, Inc.
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Consumption of a Limosilactobacillus Supplement on Recurrence of Uncomplicated Symptomatic Urinary Tract Infections (UTI) in Healthy Women During a 6-month Period
The goal of this clinical trial is to assess the efficacy of the probiotic Limosilactobacillus reuteri 3613 for the decrease or prevent UTI occurrence in women ages 18-65 with a confirmed medical history of recurrent uncomplicated UTIs compared to a Placebo (the study medication without the probiotic)
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Adult women with a confirmed medical history of recurrent uncomplicated UTIs meeting all the eligibility criteria will be allocated in two study arms: test and placebo.
Approximately 65 subjects per group will be enrolled to assure that approximately 50 subjects in each group complete the study.
the study will be conducted in Ireland.
The study will last approximately six month for each subject and will consist of 5 visits.
The L. reuteri 3613 will be taken daily for 6 months and the frequency of UTIs will be assessed to determine the potential for the probiotic to decrease or prevent UTI occurrence.
Study Type
Interventional
Enrollment (Anticipated)
130
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wafaa A Ayad, MD, PhD
- Phone Number: 6098061950
- Email: wafaa.ayad@churchdwight.com
Study Contact Backup
- Name: Oliver Chen, PhD
- Phone Number: 6098061583
- Email: oliver.chen@churchdwight.com
Study Locations
-
-
New Jersey
-
Princeton, New Jersey, United States, 08543
- Recruiting
- Church &Dwight., Inc
-
Contact:
- Wafaa A Ayad, MD, PhD
- Phone Number: 609-806-1950
- Email: wafaa.ayad@churchdwight.com
-
Contact:
- Oliver Chen, PhD
- Phone Number: 609 806 1583
- Email: oliver.chen@churchdwight.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Be able to give voluntary, written, informed consent to participate in the trial.
- Be between 18-65, inclusive.
- Has a BMI between 18.5 to 40 kg/m2, inclusive.
- Has a history of recurrent UTIs, defined as ≥ 3 episodes in the past year, of which two were approximately in the past 6 months immediately prior to their screening visit (Visit 1), at the discretion of the investigator. At least one episode must be diagnosed medically and treated by a health care professional, the remaining two may be self-reported.
- Willing to maintain existing dietary and physical activity patterns throughout the trial period.
Willing to comply with the trial protocol and consume the investigational product daily for the duration of the trial.
-
Exclusion Criteria:
- Individuals who are on unstable medications (defined as prescribed medications which in the opinion of the investigator may impact the outcomes of the study (defined as prescribed medications for which participant only takes periodically or 'as needed').
- Individuals with a history of UTIs who have experienced >5 UTIs in the 6 months prior to their Baseline Visit (Week 0).
- Participants with clinically significant abnormal laboratory results at their screening visit (from urine culture, urinalysis, and safety blood assessments) which, in the opinion of the investigator, would impact the efficacy of the trial or the safety of the participant.
- Individuals who are pregnant, breastfeeding, or wish to become pregnant during the trial.
- Individuals currently of childbearing potential, but not using an effective method of contraception
- Individuals who have taken oral antibiotics (or topical antibiotics in their urogenital area) within the previous 30 days prior to their Baseline Visit (Visit 2).
- Individuals with a current history of drug abuse (self-report) and/or alcohol abuse (>2 standard alcoholic drinks per day) within the 6 months prior to Baseline Visit (Visit2).
- Uses tobacco or smoking-related products (including, but not limited to cigarettes, cigars, chewing tobacco, e-cigarettes), and nicotine products (e.g., nicotine gum and/or nicotine patches).
- Individuals currently consuming an extremely restrictive diet, or in the previous 3 months prior to their Baseline Visit or planning to consume a restrictive diet during the trial.
- Individuals who are not willing to adhere to dietary/supplement restrictions listed in the trial protocol (refrain from consumption of probiotic supplements, prebiotics, cranberry supplements, and D-mannose supplements; limit consumption of yoghurt, fermented foods, and cranberries to no more than once per week).
- Individuals with allergies or sensitivities to ingredients that would preclude intake of the investigational products.
- Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 30 days prior to their Screening Visit (Visit 1) for this trial.
- Individuals that have a significant acute or chronic coexisting illness such as renal diseases (renal failure, nephrolithiasis), anatomical urinary tract abnormalities, intestinal disease, severe uncontrolled metabolic or cardiovascular disease (such as diabetes or hypertension), anticoagulant therapy, cancer, or HIV, or any condition which contraindicates, in the investigator's judgement, entry to the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: Limosilactobacillus Supplement
Capsules containing Probiotic taken daily for 6 month
|
Daily for 6 month
Other Names:
|
Placebo Comparator: Placebo
Capsules containing Microcrystalline cellulose, magnesium stearate taken Daily for 6 month
|
Daily for 6 month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence rate of symptomatic UTI
Time Frame: 6 months
|
To evaluate in healthy women who experience recurrent UTIs, the effect of 6 months of daily supplementation of the investigational product on incidence rate of symptomatic UTIs.
|
6 months
|
Proportion of subjects experiencing ≥1 symptomatic UTI
Time Frame: 6 months
|
Proportion of participants per product group experiencing ≥1 symptomatic UTI (as determined by urine culture) during the 6-month intervention period (from Baseline Visit [V2] to Final Visit [V5]).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UTI symptom severity
Time Frame: 6 months
|
Change in UTI symptom severity of participants with symptomatic UTI between product groups comparing Baseline (Week 0) with scores to scores at V 5 for
|
6 months
|
Proportion of subjects experiencing different numbers of UTI
Time Frame: 6 months
|
Proportion of participants per product group experiencing 0, 1, 2, 3, or more symptomatic UTI during the 6-month intervention period from V2 to Final V5
|
6 months
|
Total UTI count
Time Frame: 6 months
|
Difference in total number of UTIs per group (probiotic treatment compared to placebo group) during the 6-month intervention period from V2 to Final V5
|
6 months
|
Time for the first UTI
Time Frame: 6 months
|
Difference in time from Day 0 to the first UTI occurrence between product groups, during the 6-month intervention period from Day 0 to V5
|
6 months
|
Vaginal pH change
Time Frame: 6 months
|
Change in vaginal pH over time from Visit 2 to Visit 5, between product groups
|
6 months
|
Quality of Life change
Time Frame: 6 months
|
Change in Quality of Life questionnaire using Likert scale over time from Visit 2 to Visit 5, between product groups
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time for vaginal presence of the probiotic
Time Frame: 6 months
|
To evaluate in healthy women who experience recurrent UTIs, the effect of 6 months of daily supplementation of the investigational product on the time it takes for the probiotic to reach the urogenital tract.
The probiotic in vaginal samples will be measured visits 2-5.
|
6 months
|
Vaginal microbiome
Time Frame: 6 months
|
Modulation of the vaginal microbiome analyzed using Shotgun metagenomic sequencing from Baseline (Week 0) to Visit 5 (Week 24) compared between groups.
|
6 months
|
Vaginal presence of the probiotic
Time Frame: 6 months
|
To evaluate the proportion of participants with vaginal swabs positive for the probiotic at Baseline (Visit 2) compared to Visit 5 (Week 24, end of intervention) between product groups.
|
6 months
|
Safety assessment
Time Frame: 6 months
|
Occurrence of any Adverse Events (AEs/SAEs).
|
6 months
|
Tolerability
Time Frame: 6 months
|
Vital signs (Blood Pressure, Heart Rate, and Temperature).
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2021
Primary Completion (Anticipated)
June 1, 2023
Study Completion (Anticipated)
June 1, 2023
Study Registration Dates
First Submitted
March 2, 2023
First Submitted That Met QC Criteria
March 20, 2023
First Posted (Actual)
March 31, 2023
Study Record Updates
Last Update Posted (Actual)
March 31, 2023
Last Update Submitted That Met QC Criteria
March 20, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AFCRO-138
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Symptomatic Urinary Tract Infections
-
Paratek Pharmaceuticals IncCompletedCystitis | Uncomplicated Urinary Tract InfectionUnited States
-
Iterum Therapeutics, International LimitedCompletedUncomplicated Urinary Tract InfectionsUnited States
-
National University of Ireland, Galway, IrelandHealth Research Board, IrelandCompletedUncomplicated Urinary Tract InfectionIreland
-
IRCCS Policlinico S. MatteoUnknownDiverticular Disease | Symptomatic Uncomplicated Diverticular DiseaseItaly
-
Amneal Pharmaceuticals, LLCSymbio, LLCCompletedUncomplicated Urinary Tract InfectionsUnited States
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedAntibiotic Resistant Infection | Uncomplicated Urinary Tract InfectionBangladesh
-
The Royal College of Surgeons of EnglandUniversity College, LondonCompletedUncomplicated Lower Urinary Tract Symptoms
-
University Hospital, RouenCompletedAcute Uncomplicated Bacterial CystitisFrance
-
Merck Sharp & Dohme LLCCompletedPyelonephritis | Complicated Urinary Tract Infection | Urinary Tract Infection (UTI) | Uncomplicated Pyelonephritis
-
GlaxoSmithKlineSuspendedUncomplicated Urinary Tract InfectionsUnited States
Clinical Trials on Limosilactobacillus reuteri 3613
-
Malo ClinicCompletedPeri-implant MucositisPortugal
-
University Hospital Center of MartiniqueUniversity Hospital, Limoges; Reims University Hospital; BioGaia AB; Regional Health... and other collaboratorsNot yet recruitingChlordecone (Kepone) ToxicityMartinique
-
Universidade do Extremo Sul Catarinense - Unidade...Recruiting
-
National Yang Ming UniversityBened Biomedical Co., Ltd.Recruiting
-
Lama Medical Care s.r.o.BioGaia ABUnknownDyspepsia | H. Pylori InfectionSlovakia
-
Innovacion y Desarrollo de Estrategias en SaludBioGaia ABCompletedIrritable Bowel SyndromeChile, Mexico
-
The Hospital for Sick ChildrenUnknownColic | Infantile
-
BioGaia ABAtlantia Food Clinical Trials; CTC Clinical Trial Consultants ABRecruitingColic, InfantileIreland, Sweden
-
Vastra Gotaland RegionBioGaia ABCompleted
-
Glac Biotech Co., LtdRecruitingChronic Obstructive Pulmonary Disease | Type 2 DiabetesTaiwan